Dr. Grey AI

Icatibant (Firazyr)

Peptide

Icatibant is a synthetic decapeptide and selective bradykinin B2 receptor antagonist. FDA-approved in 2011 for acute hereditary angioedema (HAE) attacks. Phase III FAST trials showed median symptom relief in 2 hours vs 12-19.8 hours placebo/comparator. Administered as 30mg subcutaneous injection, self-injectable by patients.

Quick Answer

What it is

Icatibant is a synthetic decapeptide and selective bradykinin B2 receptor antagonist. FDA-approved in 2011 for acute hereditary angioedema (HAE) attacks.

Key findings

  • Grade A: Time to Symptom Relief (Hereditary Angioedema)
  • Grade A: Primary Symptom Relief Onset (Hereditary Angioedema)
  • Grade A: Cutaneous Attack Resolution (Hereditary Angioedema)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Icatibant (Firazyr)

Quick Facts: Icatibant (Firazyr)

  • Best Evidence:Grade A
  • Conditions Studied:1
  • Research Outcomes:7
  • Grade A Findings:5
  • Grade B Findings:1
  • Key Effect:Hereditary Angioedema
A5
B1
C0
D1
1 conditions · 7 outcomes

Detailed Outcomes

A
Time to Symptom Relief
FAST-3: 2.0 hours to 50%+ symptom reduction vs 19.8 hours placebo (P<0.001). FAST-2: 2.0 hours vs 12.0 hours tranexamic acid (P<0.001).
large↓Improves
A
Primary Symptom Relief Onset
FAST-3: Median onset of primary symptom relief 1.5 hours vs 18.5 hours placebo (P<0.001).
large↓Improves
A
Cutaneous Attack Resolution
Rapid and stable relief from cutaneous attacks demonstrated in Phase III trials.
large↑Improves
A
Abdominal Attack Resolution
Significant reduction in abdominal attack symptoms with rapid onset of action.
large↑Improves
A
Laryngeal Attack Resolution
Effective for potentially life-threatening laryngeal attacks, though emergency medical care still recommended.
large↑Improves
B
Safety/Tolerability
5 human trials support this finding. Human clinical trial data available.
small↑Improves
D
Reproductive Outcomes
2 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves

Research Citations (24)

Safety, efficacy, and pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: A phase 3, open-label study.
(2023)
PMID: 37381768
Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial.
(2023)
PMID: 36610464
Is Icatibant Safe for the Treatment of Hereditary Angioedema During Pregnancy?
(2022)
PMID: 36044174
A multicenter, open-label, randomized, proof-of-concept phase II clinical trial to assess the efficacy and safety of icatibant in patients infected with SARS-CoV-2 (COVID-19) and admitted to hospital units without invasive mechanical ventilation: study protocol (ICAT-COVID).
(2022)
PMID: 35413921
Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study.
(2020)
PMID: 31672405
Icatibant, another piece of the therapeutic puzzle regarding hemodynamic side effects of angiotensin-converting enzyme inhibitors.
(2019)
PMID: 31462265
Effect of icatibant on angiotensin-converting enzyme inhibitor-induced angioedema: A meta-analysis of randomized controlled trials.
(2019)
PMID: 31290163
Self-administration of icatibant in acute attacks of Type I hereditary angioedema: A case report and review of hereditary angioedema.
(2019)
PMID: 31579975
Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice.
(2017)
PMID: 27926986
Icatibant outcome survey: patient experience with hereditary angioedema treatment
(2015)
PMID: 26449536

Related Peptides

Ecallantide (Kalbitor)

Peptide

1 shared condition · 6 outcomes

Ecallantide is a 60-amino acid recombinant polypeptide kallikrein inhibitor for hereditary angioedema. FDA-approved December 2009. First subcutaneous HAE treatment approved. EDEMA3 & EDEMA4 Phase 3 (n=168): Significantly greater symptom improvement at 4h vs placebo (P<0.01). Treatment outcome score 53.4 vs 8.1 placebo (P=0.003). Effect apparent within 2h and maintained through 24h. SAFETY CONCERN: Anaphylaxis risk 3.9% - must be administered by healthcare professional with anaphylaxis treatment available.